9th April 2019
Changes in the glycosylation pattern of cell surface and secreted glycoproteins are common in malignant transformations and cancer progression, (1). Prostate-specific antigen (PSA), is a glycoprotein enzyme secreted by the prostate gland that is often used for diagnosing and predicting progression of prostate cancer in men. Recent advances in the field of glycobiology […]
9th April 2019
3rd October 2018
Proprietary process with validated improvement in delivery and performance
OptimersTM in 12 weeks
Aptamer Group is pleased to announce availability of OptimersTM – the new standard for our custom development services.
Aptamer Group is dedicated to continually improve its service offerings to identify the best reagent(s) from within our vast aptamer libraries in the […]
29th August 2018
At Aptamer Group, every custom aptamer project begins with a feasibility study. The target and assay matrix are tested for compatibility and stability with the aptamer library, under a variety of conditions. At this early stage it is important to understand the optimal strategy for the selection, address any potential issues and […]
9th August 2018
Aptamers continue to demonstrate advantages in platforms and applications which require specific detection of small molecule targets.
There has been a growth in the use of point of care devices across a range of applications and assay types due to a need for rapid and reliable analysis (Vashist 2017). Aptamers are perfectly suited for […]
1st August 2018
Scientists from the Technical University of Denmark, led by Krishna Kant have published a new review in Biotechnology Advances including aptamer-based approaches for the rapid detection of food-borne pathogens.
Food borne diseases, caused by the consumption of foods contaminated with pathogens or their toxins, are one of the major burdens to public health, causing […]
Arron Tolley, CEO – I’m delighted to announce that Aptamer Group Ltd, has recently closed its Series A investment round; attracting international interest and securing $2.2m of funding from overseas investors, to support its pioneering aptamer development pipeline.
Aptamer technology is rapidly evolving and will continue to have a significant impact on the life sciences market […]
Aptamers excel as binding reagents in ELISA replacement assays for antibiotics in complex media such as plasma, milk and others
18th May 2018.
Traditionally small molecules, such as antibiotics, have been difficult targets for ELISA development. Aptamer Group has selected aptamers that bind to small molecules, previously inaccessible to other binding technologies. Utilising our state-of-the-art automation and parallel processing techniques, we can select high affinity and highly specific aptamers against small molecule targets, in solution. These […]
18th April 2018
Previously we introduced aptamers as a tool for cell specific staining. Here we have taken this technology a step further to demonstrate that aptamers can monitor disease progression in cancer.
By utilising our selection methodology, we can rapidly isolate aptamers against cells in different disease states. Through this process we have been able to identify […]
Cell specific staining in Confocal Imaging
Over the next few weeks we are going to look at examples of where we have developed aptamers for cell imaging.
One of the most common methods for understanding the structure and function of biological systems is through confocal microscopy. Cell imaging technologies have been advancing at a rapid pace, however […]
22nd August, 2017.
A biomarker is a measurable indicator showing the presence or severity of a disease state. Using biomarkers to differentiate between healthy and diseased cells can enable the development of specific diagnostics, research tools and targeted therapeutics.
Biomarker Discovery using Aptamers
Traditional biomarker discovery is a long process and relies on multiple comparisons using various […]